Nowadays, there is an increasing need for fast HPLC separations characterized by high efficiency and good resolution. The ultra-high pressure liquid chromatography (UHPLC) has been considered suitable to meet this challenge, but it was found that this method also has serious disadvantages. Currently, the range of applications of the UHPLC in the analysis of pharmaceutical substances and dosage forms is discussed in the literature [1- 2].  In this study we investigated the consequences of shortening the analysis time. Bosentan, a non-peptide antagonist of human endothelin receptors, was chosen as an example due to its therapeutic importance and lack of analytical methods described. Two high-performance liquid chromatography methods were compared, both in the reversed phase, with UV detection at 220 nm by performing the validation of the methods and comparing the resulting performance characteristics. The first separation (method A) has been achieved on Kinetex column, 2.6m C18 100A, 150 x 4.60 mm, the second – fast (method B) employed Kinetex column, 1.7m XB-C18 100A  50 x 3.0 mm. Both methods were performed with a buffered mobile phase containing 0.1% of triethylamine (TEA) in water brought to the pH 2.5 with phosphoric acid and methanol as the solvent A and acetonitrile as the solvent B. Gradient program was used and flow rate 0.8 ml/min and 0.4 ml, for the methods A and B respectively. The methods were validated according to the ICH guidelines for specificity, precision on the specified and LOQ limits, intermediate precision, accuracy, linearity (correlation coefficient=0.999) and robustness. The robustness was confirmed using  four factors: the mobile phase pH, the flow rate of the mobile phase, column temperature and the other batch of the column. The limits of detection and quantification were established. Both validated methods  fulfilled  the acceptance criteria. The method B was 3.5 times faster than the method A, but the method A showed much better sensitivity (LOQ 0.0132 and 0.1505 mg/mL for method A and B, respectively) and resolution (R_s between compound B and bosentan 3.39 and 1.75 for method A and B, respectively).  This  lowered sensitivity limits the  utility of the method B, especially in the analyses of low levels of active substances (e.g. bioanalysis, validation of the cleaning procedures).

The project was supported  by The National Centre for Research and Development, under the contract No. UDA-POIG.01.03.01-14-062/09-00.

References:

[1]   D. Guillarme, D.T.T. Nguyen, S. Rudaz. J.L. Veuthey, Method transfer for fast liquid chromatography in pharmaceutical analysis: Application to short columns packed with small particle. Part I: Gradient experiments, Eur. J. Pharm. Sci. 68 (2008) 430-440.

[2]   R. Kormany, J. Fekete, D. Guillarme, S. Fekete, Reliability of computer-assisted method transfer between several column dimension packed with 1.3-5 mm core-shell particles and between various instruments, J. Pharm. Biomed. Anal. 94 (2014) 188-195.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/31194 must be provided.

1. Influence of the side chain on the cytotoxicity of betulin derivatives
2. Synthesis of new 5H-indolo[2,3-b]quinoline derivatives with a high selective cytotoxic activity
3. Hplc study of Cilostazol tablets: assay and release profile determination
4. What modern crystallography can add to pharmaceutical research?
5. Antiproliferative and cytotoxic effect of vitamin D₃ and its derivatives on the selected cells with a higher proliferative potential
6. Application of the new data processing method for photodiode array detector in the analysis of drug substances
7. Improved manufacturing process of bosentan monohydrate.
8. Development and validation of the GC method for quantitative determination of semi-volatile solvents in pharmaceutical substance Bosentan
9. The dissolution model and comparison of the analytical methods used for the assay of sunitinib malate released from capsules
10. Pharmaceutical  technologies  – why do they have to be innovative
11. A novel convergent synthesis of the prostaglandin F_2α analogues
12. Assessment of selected synthesis of bosentan towards elimination of known impurities.
13. Application of HPLC for studying purity, content and release profile of temozolomide capsules
14. New cyclic dermorphin analogues containing a carbonyl bridge
15. Investigation of unknown impurities in cyclic dermorphin analogue by HPLC-MS
16. Comparative permeation studies of tacalcitol through the human skin from brand product versus generic product
17. Development and validation of the HPLC-UV method for impurities determination in duloxetine hydrochloride
18. 5H-indolo-[2,3-b]quinolines loaded polymeric micelles
19. Physicochemical characterization of sunitinib and its impurities
20. Vitamin D analogs enhance the activity of imatinib mesylate in human non-small cell lung cancer model
21. Colon cancer treatment with the use of vitamin D analogs and irinotecan 
22. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
23. Experimental and theoretical charge density studies on a model analogue of vitamin D
24. Synthetic Technologies of Pharmaceutical Substances
25. The development of the spectrofotometric and HPLC method for studying enteric coated capsules containing Duloxetine Hydrochloride active substance
26. Stability study of the coated tablets containing clopidogrel bisulfate as the active substance
27. Development of RP HPLC method for the analysis of calcipotriol in cream and ointment
28. Opimisation of preparation of TZ-6
29. HPLC method as an analitycal control of synthesis and determination of TZ-S
30. The synthesis of ezetimibe with high stereochemical purity
31. Investigation of unknown impurity of TD-S by HPLC-MS
32. The influence of (24R)-1,24- dihydroxyvitamin D₃ on the anticancer activity of 5-fluorouracil in human colon cancer model
33. The use of the hyphenated LC-MS/MS technique for the characterisation of impurity profile of Quetiapine during drug development
34. A novel synthesis of 19-nor analogs of vitamin D
35. The influence of novel analogs of vitamin D₃ on the antiproliferative activity of cisplatin or doxorubicin on human promyelocytic leukaemia cell line HL-60 
36. New amino acid and peptide derivatives of 5H-indolo[2,3-b]quinoline and their biological activity.
37. The evaluation of tolterodine tartrate synthesis based on patent EP 0 325 574 B1.
38. Disubstituted indolo[2,3-b]quinoline derivatives - the cytotoxic activity in vitro against various human tumor cell lines.
39. Mono substituted 5H- and 6H-indolo[2,3-b]quinoline derivatives and their ability to overcome the barrier of drug resistance.
40. Synthesis of selected ¹⁴C radiolabelled compounds in recent investigations of new analytical method applied in accelerated drug development (EUMAPP).
41. Isolation, structural elucidation and characterization of impurities in latanoprost
42. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
43. New rosiglitazone salts
44. New calcipotriol analogs, their toxicity and antitumor activity in vivo in comparison to the affinity with VDR and DBP
45. High-yielded method of synthesis of voriconazole.
46. New amino acid derivatives of 6H-indolo[2,3-b]quinolines
47. Polimorphism of Active Pharmaceutical Ingredients
48. QUINONES AND HYDROQUINONES SEPARATION AND DETERMINATION BY HPLC CHROMATOGRAPHY
49. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
50. DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.
51. ANTITUMOR EFFECT OF CISPLATIN OR FLUOROURACIL IN COMBINED TREATMENT WITH (24R)-1,24-DIHYDROXYVITA- MIN D₃
52. COMBINATION OF: IMATINIB, PRI-2191 AND CYTOSTATICS - THE ANTIPROLIFERATIVE EFFECTS ON HL-60 LEUKEMIA CELL LINE
53. ANTIPROLIFERATIVE ACTIVITY IN VITRO OF DIASTEREOMERIC ANALOGUES OF VITAMIN D3 AGAINST NORMAL AND CANCER CELL LINES
54. NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC^®) SYNTHESIS.